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Background: Coronary heart disease is highly prevalent and a major cause of morbidity and 
mortality in diabetic patients. The aim of this study was to assess the major risk factors and 
their predictor score for coronary heart diseases in diabetic patients.
Methods: The present study was conducted in al-Madinah, Kingdom of Saudi Arabia. Using a 
cross-sectional case control study, 262 outpatient diabetics and 264 matched control   subjects were 
examined for the risk factors and risk predictor scores for ischemic heart disease. The mean age of 
the patient and control groups was 49.61 ± 12.93 years and 48.39 ± 11.60 years, respectively.
Results: Diabetic patients had significantly higher positive family history of diabetes, but no 
significant difference regarding their family history of hypertension. There was a significantly 
higher body mass index (33.67 kg/m2), glycosylated hemoglobin (7.26%), significantly higher 
cholesterol, low-density lipoprotein, and triglyceride in diabetics compared to control. Diabetic 
patients had higher risk for developing coronary heart disease with a mean risk score of 6.07 
while the control subject risk score was −6.81. However, females showed significantly higher 
risk for coronary heart diseases than did males.
Conclusion: Our study replicates the known fact of higher risk in diabetes, but higher risk of 
coronary heart disease in female diabetics compared with male diabetics.
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Introduction
Cardiovascular disease is the leading cause of death among patients either with type I or 
type II diabetes mellitus (DM).1 The prevalence of coronary heart disease (CHD) is 
5.5% in the Kingdom of Saudi Arabia, with a prevalence in males and females of 6.6% 
and 4.4%, respectively. Urban Saudis have a higher CHD prevalence (6.2%) compared 
to rural Saudis (4%).2 Patients with diabetes, but without other conventional risk fac-
tors for atherosclerosis, have a risk of death from CHD 2–4 times that of age-matched 
controls.3 Those with type II DM commonly have other associated risk factors, such as 
hypertension or dyslipidemia, thus further increasing their cardiovascular risk. Women 
with diabetes have an increased risk of cardiovascular death of up to 7.5 times that of 
nondiabetic women. Diabetic women do not have the premenopausal benefit seen in 
the general female population.3–5
Individuals with diabetes and CHD fare worse than do other patients with 
CHD. Those who present with a myocardial infarction (MI) are at increased risk 
of dying from their event or of developing heart failure.6,7 They benefit less from 
thrombolysis in the setting of an acute MI.5,6,8 Coronary artery bypass surgery 
and percutaneous transluminal coronary angioplasty are associated with greater 
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  long-term mortality in diabetic patients than in those with-
out diabetes.7,9,10   Therefore,   prevention or early detection 
of CHD is important to ensure early medical interventions 
to improve outcome.
The past decade has witnessed major strides in the preven-
tion of CHD through modification of its causes. The most 
dramatic advance has been the demonstration that aggressive 
medical therapy will substantially reduce the likelihood of 
recurrent major coronary syndromes in patients with estab-
lished CHD (secondary prevention). The American Heart 
Association (AHA) and the American College of Cardiology 
(ACC) have published joint recommendations for medical 
intervention in patients with CHD and other forms of ath-
erosclerotic disease.11,12
The present statement is being published jointly by the 
AHA and ACC to outline current issues and approaches to 
global risk assessment for primary prevention. The approaches 
described in this statement can be used for guidance at several 
levels of primary prevention; however, the statement does 
not attempt to specifically link risk assessment to treatment 
guidelines for particular risk factors.   Nonetheless, it provides 
critical background information that can be used in the devel-
opment of new treatment guidelines.13,14
The quantitative relationship between these risk factors 
and CHD risk has been elucidated by the Framingham Heart 
Study.14 The predisposing risk factors are those that worsen 
the independent risk factors. Two risk factors, obesity and 
physical inactivity, are designated major risk factors by the 
AHA.15,16 The adverse effects of obesity are worsened when 
it is expressed as abdominal obesity,15 an indicator of insulin 
resistance.
The other predisposing risk factors are obesity, physical 
inactivity, and family history of premature CHD, ethnic char-
acteristics, psychosocial factors, elevated serum triglycerides, 
elevated serum homocysteine, prothrombotic factors, and 
inflammatory markers.
The elevated inflammatory biomarkers such as high-
sensitivity C-reactive protein predict CHD diseases,17 and 
death independently of other cardiovascular risk factors.18
Methods
This is a case-control study carried out in al-Madinah 
al-  Munawarah, Kingdom of Saudi Arabia. The study was 
approved by the Scientific Research Deanship committee of 
Taibah   University. Informed consent was obtained from all 
participants. The aim of this study was to assess the major 
risk factors and their predictor score for CHDs in diabetic 
patients.
Patients
The study included 526 subjects, who were sorted into 
two groups: Group A included 262 patients (118 males 
and 144 females) diagnosed as diabetics according to the 
American Diabetes Association (ADA) definition of diabetes, 
and who were selected by using a simple random sample at 
the outpatient clinic of the Diabetic Patients Center in King 
Fahad Hospital; a matched Group B for age and sex included 
264 patients (122 males and 142 females) with no diabetes 
or cardiac problems, who were randomly selected from other 
outpatient clinics.
Blood analysis
Each subject in both groups provided demographic data 
using a structured questionnaire in Arabic. All subjects 
were examined clinically and information pertaining to 
age, sex, habits, and health status was recorded. Weight 
was measured in kilograms using a standard beam scale 
with subjects barefoot and wearing light clothes. Weight 
was recorded to the nearest 100 g. Height was measured 
in centimeters on a calibrated height board attached to 
the beam scale. Obesity was assessed using body mass 
index (BMI) and patients were classified as overweight 
(BMI = 25.0–29.9 kg/m2), obese (BMI = 30.0–39.9 kg/m2), 
and morbid obesity (BMI = 40.0 kg/m2).16
Blood samples were collected from both control and 
patient groups for a series of laboratory investigations using 
standard protocols for estimation of fasting and postpran-
dial blood glucose, serum total cholesterol, triglycerides, 
  high-density lipoprotein (HDL), low-density lipoprotein 
(LDL) cholesterol, serum creatinine, and glycosylated 
hemoglobin (HbA1C) (Bio-Rad DiaSTAT Hemoglobin A1C 
Program; Bio-Rad Laboratories, Hercules, CA). The nor-
mal range for people without diabetes (4.4%–6.4%) was 
estimated. HbA1Cof ,7% was considered as good glyce-
mic control, and above 7% considered as poor control.19,20   
Cholesterol levels below 5.18 mmol/L of blood were con-
sidered normal, between 5.18 and 6.18 mmol/L were con-
sidered borderline high, and above 6.18 mmol/L were high. 
Triglyceride   levels ,150 mg/dL (,1.7 mmol/L) were 
defined as normal, 150–200 mg/dL (1.7–2.3 mmol/L) as 
increased risk, and .200 mg/dL (.2.3 mmol/L) as high 
risk. HDL levels .40 mg/dL (.1.04 mmol/L) were taken 
as normal and a desirable level, between 30–40 mg/dL 
as increased risk, and ,30 mg/dL as high risk. LDL lev-
els were   optimal if less than 100 mg/dL (,1.3 mmol), 
borderline high at 130–159 mg/dL (3.3–4.1 mmol), and 
high .160–189 mg/dL (.4.1 mmol).21–24
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The major independent risk factor assessed was cigarette 
smoking. Smoking was classified as current smokers,   
ex-smokers (having stopped at least 1 year before),25 and 
nonsmokers. Another independent risk factor was elevated 
blood pressure; two readings of blood pressure were made on 
the right arm using a standard mercury sphygmomanometer 
in the physician’s consulting room after the person was seated 
for 5 minutes. Hypertension was defined according to the 
Seventh Report of the Joint National Committee on Preven-
tion, Detection, Evaluation, and Treatment of High Blood 
Pressure. Elevated serum, total cholesterol, LDL cholesterol, 
low serum HDL cholesterol, DM, and advancing age were 
also considered risk factors. The Global Risk Assessment 
Score and the low-risk state were defined according to the 
Framingham Heart Study.14
Statistical analysis
Data were analyzed using SPSS software (v. 13; SPSS Inc, 
Chicago, IL). Descriptive statistics (mean, standard devia-
tion, frequency, and relative frequency) were used to describe 
demographic and observational data. Student’s t-test for 
continuous variables was used.
Results
The mean age value was 49.61 ± 12.93 years and 48.39 ± 11.60 
years in patient and control groups, respectively. Both groups 
were matched by number, sex, mean age, nonsmokers, and 
family history of hypertension and diabetes. The results show 
that diabetic patients have higher family history of diabetes, 
while the analysis showed no significant differences regard-
ing family history of hypertension (Table 1).
Though both groups were obese, BMI in diabetics 
(33.63 ± 5.97 kg/m2) was more than in control group 
(31.05 ± 6.76 kg/m2), where there was a highly significant 
difference (P , 0.001). Statistical analysis shows that there 
were highly significant differences (Figure 1) in fasting, 
postprandial blood glucose and glycosylated hemoglobin 
measurements among both groups. Diabetics had higher 
fasting and postprandial blood glucose mean values (222.79 
and 236.16 mg/dL, respectively). An analysis of variance test 
showed this was highly statistically significant (P , 0.001). 
On the other hand, HbA1C was also high in the diabetic group 
(7.26%) compared to the control (5.58%) and this was highly 
significant (P , 0.001) (Table 2).
We  found  that  the  mean  systolic  and  diastolic 
blood pressure values for diabetics were highest, at   
137.39 ± 20.98 mmHg and 81.29 ± 10.12 mmHg, respec-
tively, compared to 115 ± 18 mmHg and 72 ± 13 mmHg for 
the control group, which was highly statistically significant 
(P , 0.005) (Figure 2).
Figure 3 shows the blood lipid profile (total cholesterol, 
HDL, LDL, and triglycerides) measures for both groups. 
Diabetes patients had higher LDL levels, where the mean 
was 3.21 ± 0.98 mmol/dL (P , 0.005). On the other hand, 
regarding total cholesterol, LDL, triglycerides, and HDL 
there were no significant differences between diabetic and 
control groups (P . 0.05).
Figure 4 shows the total risk for patient and control 
groups. Diabetics have a higher total risk (2.57) compared to 
the control (−6.81) and this was highly statistically significant 
(P , 0.001).
Figure 5 shows the sex differences for patient and control 
groups. Female subjects in the diabetic group have a signifi-
Table 1   Distribution  of  the  descriptive  statistics  data  of  the 
family history of hypertension and diabetes mellitus in patient and 
control groups
History Number of patients
Patients Control Total
Family history of hypertension
  Negative 186 191 377
  Positive 76 73 149
Family history of diabetes mellitus
  Negative 135* 151 286
  Positive 127 117 240
Note: *P  0.05.
Table 2 Distribution of the descriptive statistics of the fasting 
and postprandial blood glucose and hbA1C in patient and control 
groups
Patients 
(Mean ± SD)
Control 
(Mean ± SD)
Fasting blood sugar (mg/dL)   86.49 ± 9.34*** 85.45 ± 9.04
Postprandial blood sugar (mg/dL) 110.82 ± 25.35*** 78.40 ± 9.31
Glycosylated hemoglobin (%)   7.26 ± 1.36***   5.58 ± 0.81
Notes: Significance at ***P  0.001
Abbreviations: hbA1C, glycosylated hemoglobin; SD, standard deviation.
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Figure 1 Body mass index for patient and control groups.
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for cardiovascular outcomes.30 Apart from the traditional risk   
factors such as hypertension, hyperlipidemia, and obesity, 
hyperglycemia is an independent risk factor for the develop-
ment of ischemic heart disease. Long-term hyperglycemia 
leads to vascular damage through several mechanisms as 
oxidative stress, formation of advanced glycation end prod-
ucts, activation of nuclear factor kappa B, and decreased 
production of nitrogen monoxide.31
Despite most of our patients having almost normal fasting 
and postprandial blood sugar levels (86.49 ± 9.34 mmHg and 
110.82 ± 25.35 mmHg, respectively), they still have increased 
risk for death from ischemic heart disease as they are already 
known to be diabetic and their HbA1C was 7.2 6 ± 1.36 mmHg. 
These still could be explained by Honolulu Heart Program, 
where they found that the deaths from CHD and total 
deaths were higher in the asymptomatic hyperglycemic and 
known diabetics compared with low normal euglycemics.32 
On the other hand, it is reported that intensive blood glucose 
control that significantly reduces HbA1C compared to con-
ventional treatment does not reduce significantly the risk of 
diabetes-related death, all-cause mortality, and risk of MI.33 
  Hyperinsulinemia and hyperglycemia might affect patients 
through the comorbidities of hypertension, dyslipidemia, and 
central body fat distribution.34,35
The anthropometrical variables, as observed in the BMI 
values obtained, show excessive weight in most patients 
in all groups where BMI of control and patients were 
31.05 ± 6.76, and 33.67 ± 6.02, respectively. These results are 
similar to those found in a multicenter study carried out with 
more than 2500 type II DM patients in 12 cities in different 
Brazilian regions.36 The high prevalence of overweight 
diabetic patients was observed by epidemiological research, 
which estimated that between 80% and 90% of individuals 
with type II DM are obese or overweight.36 The prevalence 
of obesity in diabetic patients is three times higher than in 
the population in general,  highlighting the higher significant 
body mass index observed in our study.37
However, despite awareness about the importance of 
excessive body weight for morbidity and mortality of patients 
with type II DM, the control of this variable in diabetic 
populations has rarely been emphasized in most studies.36 In 
addition, the approach to this problem in basic health care 
has been neglected, since recommendations on the control 
of these variables exist in most services, but are not accom-
panied by resources that can adequately support individuals 
in an effective change that results in weight loss.
Laboratory data indicate high prevalence of dyslipidemia 
in the patients evaluated, similar to that found in a survey 
7
6
5
4
3
2
1
0
T. Chol.
B
l
o
o
d
 
l
i
p
i
d
 
p
r
o
f
i
l
e
 
m
e
a
n
 
v
a
l
u
e
s
 
i
n
 
m
m
o
L
TG LDL
5.96 5.82
4.98 4.93
1.61 1.58
2.94 2.85
Patients
Control
HDL
Figure 3 Lipid profile for patient and control groups.
Abbreviations:  hDL,  high-density  lipoprotein;  LDL,  low-density  lipoprotein; 
T. Chol., total cholesterol; TG, triglycerides.
160
140
120
100
B
l
o
o
d
 
p
r
e
s
s
u
r
e
 
m
e
a
n
 
v
a
l
u
e
s
 
i
n
 
m
m
H
g
80
60
40
20
0
Systolic blood pressure Diastolic blood pressure
Patients
Control
81 72
115
137
Figure 2 Blood pressure for patient and control groups.
cantly higher risk for coronary disease as their risk prediction 
score within 10 years was 5% compared to 2% for males, while 
the coronary disease risk prediction score within 10 years in 
the control group was 1% for both males and females.
Discussion
This study was carried out to evaluate the risk factors of CHD 
in diabetic patients through demographic data, health habits, 
and anthropometric and biochemical profiles.
DM is known to be associated with a high risk of develop-
ing vascular complications that can lead to premature death 
and/or disability mainly by increasing the risk of MI, stroke, 
and peripheral vascular disease.26 Moreover, the National 
Cholesterol Education Program report from United States 
and guidelines from Europe consider type II diabetes to be 
a CHD equivalent, thereby elevating it to the highest risk 
category.27 Patients with DM are two to four times more likely 
to develop cardiovascular disease than those in the general 
population and have two to five times greater risk of dying 
from these diseases.28,29 There is now growing consensus that 
nondiabetic hyperglycemia measured by fasting glucose, 
postload glucose or HbA1C is a progressive, continuous risk 
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with type II DM patients performed in Rio Grande do 
Sul: 67% presented total cholesterol .200 mg/dL; 65% 
triglycerides .150 mg/dL, and 47% low HDL   cholesterol 
>50 mg/dL.38 It is known that the two main components of 
diabetic dyslipidemia are the elevated levels of triglycerides 
and the low levels of HDL-cholesterol, both considered the 
main predictors of cardiovascular diseases.2
The mean values of triglycerides and LDL cholesterol 
observed in Figure 3 were above those recommended by the 
ADA.39 For diabetic patients, ADA recommends that HDL 
cholesterol values must be higher than 45 mg/dL; however, 
in this study, mean HDL was below this level (2.94 and 
2.02 mmol/dL) in outpatient and intensive care unit diabetic 
subjects, respectively. This study also presented mean values 
of LDL-cholesterol above recommendations (133.66 mg/dL) 
in the patients evaluated, as LDL-cholesterol was 3.21 and 
1.61 mmol/dL in outpatient diabetic subjects. These results 
are similar to the results of Carolino et al31 and  Gomes et al,40 
where the prevalence of dyslipidemia was (72.5%) in the 
patients evaluated. The mean values of triglycerides and LDL 
cholesterol were above those recommended by the ADA, as 
mean values of LDL-cholesterol above recommendations 
(133.66 mg/dL) in the patients evaluated.
Such lipid profiles, accompanied by the use of medica-
tion, strongly suggests inadequate diet and lack of physical 
activity. However, the need for better control of lipid levels 
has to be considered through a more effective and safe 
follow-up of the medications in use, which can even require 
dosage alteration.41
Regarding alteration in the lipid profile, the unfavorable 
impact of dyslipidemia on cardiovascular morbidity and 
mortality are largely acknowledged, as well as the frequent 
association of these conditions with diabetes.43 Moreover, 
a significant increase occurs in morbidity of individuals with 
types I and II DM in the presence of dyslipidemia. On the 
other hand, there is plenty of evidence that the treatment of 
dyslipidemia has a favorable effect on the control of macro-
vascular disease in diabetic individuals.39,44
The Framingham Study shows the relative impact of 
diabetes is substantially greater for women than for men. 
Nondiabetic women have lower relative CHD risk compared 
to nondiabetic men. The risk of cardiovascular mortality 
and morbidity was about as great for diabetic women as 
for diabetic men.44 Our study found the total risk among 
the diabetic patients was 2.57 (female main total risk was 
5.195 ± 3.671 and the main total risk of the male patients 
was −0.60 ± 1.680). Also, the results of the present study are 
going with the results of Esteghamati et al,42 who studied the 
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prevalence of cardiovascular risk factors in an Iranian popula-
tion. Although it is suggested that the excess relative risk of 
CHD mortality in women versus men with diabetes might 
disappear after adjusting for classic CHD risk factors.46,47
In another study, which showed the high risk in females, 
the authors concluded that the sex difference was largely 
explained by the persistently more favorable survival rate 
of women.44
Conclusion
The risk predictors for CHD are high in diabetic patients and 
higher in diabetic females.
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